Evidence map›Paper›PMID 40914165›Full record

ArticleCell reports. Medicine2025

Lung virome convergence precedes hospital-acquired pneumonia in intubated critically ill patients.

Hussein Anani, Grégory Destras, Simon Bulteau, Louise Castain, Quentin Semanas, Gwendolyne Burfin, Mélanie Petrier, Florian P Martin, Cecile Poulain, Robert P Dickson and 3 more

2 registry-linked trialsAbstract read
In one paragraph

Article in Cell reports. Medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 2 registered trials, which are not on this map. Cited by 10 papers.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT02003196 completednot on this map

Effects of Viral Reactivation on Outcomes of Brain-injured Patients ( IBIS-VIRUS)

TypeobservationalSponsorNantes University HospitalRan2014 to 2020Enrolled375ConditionsBrain Injury
NCT04793568 phase2unknown statusnot on this map

Human Recombinant Interferon Gamma-1b for the Prevention of Hospital-acquired Pneumonia in Critically Ill Patients: a Double-blind, International, Phase 2, Randomized, Placebo-controlled Trial - the PREV-HAP Study

TypeinterventionalSponsorNantes University HospitalRan2021 to 2023Enrolled109ConditionsCritically Ill PatientsArmsRecombinant Interferon gamma 1b (IMUKIN®), Recombinant Interferon gamma 1b placebo
3 · Its place in the literature

Who cites it

10 citing papers in PubMed.

  1. Review
  2. Journal of bacteriology · 2026
    Review
  3. Article
  4. Review
  5. Review
  6. Review
  7. Article
  8. Metagenome-assembled complete genome ofMicrobiology resource announcements · 2025
    Article
  9. Article
  10. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Hussein AnaniGenEPII Sequencing Platform, Institut des Agents Infectieux, Hospices Civils de Lyon, Lyon, France; CIRI, Centre International de Recherche en Infectiologie, Team VirPath, University Lyon, Inserm, U1111, Université Claude Bernard Lyon 1, CNRS, UMR5308, ENS de Lyon, Lyon, France.
Grégory DestrasGenEPII Sequencing Platform, Institut des Agents Infectieux, Hospices Civils de Lyon, Lyon, France; CIRI, Centre International de Recherche en Infectiologie, Team VirPath, University Lyon, Inserm, U1111, Université Claude Bernard Lyon 1, CNRS, UMR5308, ENS de Lyon, Lyon, France; Laboratoire de Virologie, Institut des Agents Infectieux, Laboratoire associé au Centre National de Référence des Virus des Infections Respiratoires, Hospices Civils de Lyon, Lyon, France.
Simon BulteauNantes Université, Center for Research in Transplantation and Translational Immunology, UMR 1064, F-44000 Nantes, France.
Louise CastainNantes Université, Center for Research in Transplantation and Translational Immunology, UMR 1064, F-44000 Nantes, France; Nantes Université, CHU Nantes, Service de virologie, F-44000 Nantes, France.
Quentin SemanasGenEPII Sequencing Platform, Institut des Agents Infectieux, Hospices Civils de Lyon, Lyon, France.
Gwendolyne BurfinGenEPII Sequencing Platform, Institut des Agents Infectieux, Hospices Civils de Lyon, Lyon, France; Laboratoire de Virologie, Institut des Agents Infectieux, Laboratoire associé au Centre National de Référence des Virus des Infections Respiratoires, Hospices Civils de Lyon, Lyon, France.
Mélanie PetrierNantes Université, Inserm, CHU Nantes, Center for Research in Transplantation and Translational Immunology, UMR 1064, F-44000 Nantes, France.
Florian P MartinNantes Université, Inserm, CHU Nantes, Center for Research in Transplantation and Translational Immunology, UMR 1064, F-44000 Nantes, France.
Cecile PoulainNantes Université, Center for Research in Transplantation and Translational Immunology, UMR 1064, F-44000 Nantes, France.
Robert P DicksonDepartment of Internal Medicine, Division of Pulmonary and Critical Care Medicine, University of Michigan Health System, Ann Arbor, MI, USA; Department of Microbiology and Immunology, University of Michigan Medical School, Ann Arbor, MI, USA; Weil Institute for Critical Care Research & Innovation, Ann Arbor, MI, USA.
Céline Bressollette-BodinNantes Université, Center for Research in Transplantation and Translational Immunology, UMR 1064, F-44000 Nantes, France; Nantes Université, CHU Nantes, Service de virologie, F-44000 Nantes, France. Electronic address: celine.bressollette@univ-nantes.fr.
Antoine RoquillyNantes Université, Inserm, CHU Nantes, Center for Research in Transplantation and Translational Immunology, UMR 1064, F-44000 Nantes, France; Nantes Université, CHU Nantes, Service d'Anesthesie Réanimation, F-44000, Nantes, France; Department of Microbiology and Immunology, The University of Melbourne, The Peter Doherty Institute for Infection and Immunity; Melbourne, Victoria 3000, Australia. Electronic address: antoine.roquilly@univ-nantes.fr.
Laurence JossetGenEPII Sequencing Platform, Institut des Agents Infectieux, Hospices Civils de Lyon, Lyon, France; CIRI, Centre International de Recherche en Infectiologie, Team VirPath, University Lyon, Inserm, U1111, Université Claude Bernard Lyon 1, CNRS, UMR5308, ENS de Lyon, Lyon, France; Laboratoire de Virologie, Institut des Agents Infectieux, Laboratoire associé au Centre National de Référence des Virus des Infections Respiratoires, Hospices Civils de Lyon, Lyon, France. Electronic address: laurence.josset@chu-lyon.fr.

Funding

The role of the lung microbiome in oxygen-induced lung injuryR01HL144599 · NHLBI · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI DICKSON, ROBERT PICKETT · 2019 to 2023
$2.1M
Midcareer Investigator Award in Patient-Oriented Research in the Microbiome and Lung DiseaseK24HL159247 · NHLBI · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI Robert Pickett Dickson · 2022 to 2026
$625k
The Gut Microbiome and Acute Muscle Loss in SepsisR21AR083005 · NIAMS · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI DICKSON, ROBERT PICKETT · 2024 to 2025
$372k
NHLBI NIH HHS K24 HL159247NHLBI NIH HHS R01 HL144599NIAMS NIH HHS R21 AR083005
6 · The paper itself

Abstract

Hospital-acquired pneumonia (HAP) is one of the most common nosocomial infections, leading to significant morbidity and mortality in critically ill patients. HAP is previously associated with dysbiosis of the microbiota. However, the composition of the lung virome and its role in HAP pathogenesis remain unclear. Here, we longitudinally analyze the endotracheal virome in 87 critically ill patients, including 48 with HAP. Within the virome dominated by Caudoviricetes, a decrease in viral beta-diversity toward a bacteriophage-dominated signature and a distinct viral-bacterial interactome is observed 5-4 days before HAP onset. Lung virome composition, viral convergence before HAP onset, and conservation of 18% of the bacteriophage signature are validated in an external cohort of 40 patients. In silico causal inference further identifies bacteriophages associated with Streptococcus and Prevotella as a key regulator of HAP onset. These findings suggest an uncovered pathophysiological mechanism of HAP with virome involvement in lung microbiota dysbiosis. The discovery and validation studies are registered at ClinicalTrials.gov (NCT02003196 and NCT04793568).

Indexed as

Cross InfectionHealthcare-Associated PneumoniaLungViromeAgedBacteriophagesClinical Trials, Phase II as TopicCritical IllnessDysbiosisFemaleHumansIntubation, IntratrachealMaleMicrobiotaMiddle AgedMulticenter Studies as TopicCaudoviricetes bacteriophagescross-kingdom interactionshospital-acquired pneumonia (HAP)intubated critically ill patientsmicrobiomerespiratory interactomeRespiratory viromeviral metagenomics

Identifiers

PMID40914165
PMCPMC12490257

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.